mal

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231

9-6-02

OW SEND and TOWNSEND and CREW LLP

SEP 11 2002 Standa Shaffer

1 9P1645

Attorney Docket No.: 15303-000510 Client Reference No.: 51838AUSM1

6360 RECEIVED

SEP 1 2 2002

TECH CENTER 1600/290

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alan R. Brooks, et al.

Application No.: 09/803,472

Filed: March 9, 2001

For: NOVEL ESTROGEN-

REGULATED G PROTEIN GAMMA SUBUNIT: COMPOSITIONS AND

METHODS OF USE

Examiner: Unassigned

Art Unit: 1645

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Alan R. Brooks, et al. Application No.: 09/803,472

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Busenia Garrett-Wackowski Reg. No. 37,330

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 925-472-5000 Fax: 925-472-8895

EGW:lls

WC 9046021 v1

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number PTO/SB/08B (10-01)

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known Application Number 09/803,472 Filing Date March 9, 2001 **First Named Inventor** SEP Brooks, Alan R. Art Unit 1645 TECH CENTER 1600/290 Examiner Name Unassigned Attorney Docket Number 15303-000510

2 2002

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	1	BOCCHINFUSO et al., Cancer Res., 59:1869-1876 (1999)	
	2	COUSE et al., Endocr. Rev., 20(3):358-417 (1999)	
	3	COUSE et al., Science, 286:2328-2331 (1999)	
	4	DOWNES et al., Genomics, 57:173-176 (1999)	
	5	KORACH, Science, 266:1524-1527 (1994)	
	6	KOZAK, J. Cell Biol., 108:229-241 (1989)	
	7	KREGE et al., Proc. Natl. Acad. Sci. USA, 95:15677-15682 (1998)	
	8	KUIPER et al., Endocrinology, 138(3):863-870 (1997)	
	9	LeMELLAY et al., J. Cell. Biochem., 75:138-146 (1999)	
	10	MORISHATA et al., j. Biol. Chem., 270(49):29469-29475 (1995)	
	11	NURNBERG et al., Eur. J. Med. Chem., 34:5-30 (1999)	
	12	REGISTER et al., J. Steroid Biochem. Mol. Biol., 64(3-4):187-191 (1998)	
	13	UEDA et al., J. Biol. Chem., 274(17):12124-12128 (1999)	
	14	YASUDA et al., J. Biol. Chem., 273(34):21958-21965 (1998)	

Examiner	Date	
Signature		
Olghature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WC 9046021 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.